Assessing the Effects of Parthenolide on Inflammation, Bone Loss, and Glial Cells within a Collagen Antibody-Induced Arthritis Mouse Model.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
09
2019
revised:
16
12
2019
accepted:
27
01
2020
entrez:
20
3
2020
pubmed:
20
3
2020
medline:
21
1
2021
Statut:
epublish
Résumé
Rheumatoid arthritis is characterised by a chronic inflammatory response resulting in destruction of the joint and significant pain. Although a range of treatments are available to control disease activity in RA, bone destruction and joint pain exist despite suppression of inflammation. This study is aimed at assessing the effects of parthenolide (PAR) on paw inflammation, bone destruction, and pain-like behaviour in a mild collagen antibody-induced arthritis (CAIA) mouse model. CAIA was induced in BALB/c mice and treated daily with 1 mg/kg or 4 mg/kg PAR. Clinical paw inflammation was scored daily, and mechanical hypersensitivity was assessed on alternate days. At end point, bone volume and swelling in the paws were assessed using micro-CT. Paw tissue sections were assessed for inflammation and pre-/osteoclast-like cells. The lumbar spinal cord and the periaqueductal grey (PAG) and rostral ventromedulla (RVM) regions of the brain were stained for glial fibrillary acidic protein (GFAP) and ionised calcium-binding adaptor molecule 1 (IBA1) to assess for glial reactivity. Paw scores increased in CAIA mice from days 5-10 and were reduced with 1 mg/kg and 4 mg/kg PAR on days 8-10. Osteoclast-like cells on the bone surface of the radiocarpal joint and within the soft tissue of the hind paw were significantly lower following PAR treatment (
Identifiants
pubmed: 32189995
doi: 10.1155/2020/6245798
pmc: PMC7073477
doi:
Substances chimiques
Sesquiterpenes
0
parthenolide
2RDB26I5ZB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6245798Informations de copyright
Copyright © 2020 B. Williams et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Pain. 2013 Nov;14(11):1255-69
pubmed: 24035349
Scand J Immunol. 2015 Feb;81(2):142-50
pubmed: 25424522
Cytokine. 2011 Dec;56(3):739-48
pubmed: 22004922
Mol Cancer Ther. 2016 Jun;15(6):1376-86
pubmed: 27197307
Anticancer Drugs. 2012 Oct;23(9):883-96
pubmed: 22797176
J Neurosci. 2017 Mar 22;37(12):3202-3214
pubmed: 28219988
Pain. 2014 Feb;155(2):388-402
pubmed: 24231652
Exp Dermatol. 2013 Aug;22(8):530-4
pubmed: 23802713
Am J Pathol. 2003 Nov;163(5):1827-37
pubmed: 14578183
FEBS Lett. 1997 Jan 27;402(1):85-90
pubmed: 9013864
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12728-33
pubmed: 22802629
Cochrane Database Syst Rev. 2015 Apr 20;4:CD002286
pubmed: 25892430
Nat Protoc. 2006;1(5):2512-6
pubmed: 17406499
Neural Plast. 2013;2013:753656
pubmed: 24024042
Eur J Pharmacol. 2011 Apr 25;657(1-3):89-96
pubmed: 21300053
Inflammopharmacology. 2017 Feb;25(1):55-68
pubmed: 28044215
J Bone Miner Res. 2004 Nov;19(11):1905-16
pubmed: 15476591
Rheumatology (Oxford). 2015 Sep;54(9):1713-23
pubmed: 25832610
Ther Clin Risk Manag. 2005 Dec;1(4):279-97
pubmed: 18360571
Arthritis Rheum. 1997 Feb;40(2):217-25
pubmed: 9041933
Pain. 2004 Jul;110(1-2):158-65
pubmed: 15275763
Nat Rev Immunol. 2014 Apr;14(4):217-31
pubmed: 24577438
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):82-90
pubmed: 22157059
Arthritis Rheum. 2012 Dec;64(12):3886-96
pubmed: 22933386
J Rheumatol. 1998 Jul;25(7):1282-9
pubmed: 9676757
J Pharm Sci. 1979 May;68(5):537-42
pubmed: 311831
Arthritis Rheum. 2008 May;58(5):1299-309
pubmed: 18438830
Arthritis Res Ther. 2011 Jun 08;13(3):R83
pubmed: 21651807
J Biomed Mater Res A. 2015 Nov;103(11):3572-9
pubmed: 25903444
Behav Brain Res. 2017 Jun 1;327:1-10
pubmed: 28286285
J Physiol. 2015 Jul 1;593(13):2955-73
pubmed: 25868084
Mol Pain. 2012 Jun 15;8:43
pubmed: 22703840
Pain. 2013 Dec;154(12):2750-8
pubmed: 23933184
Am J Pathol. 1998 Apr;152(4):943-51
pubmed: 9546355
J Pharm Pharmacol. 2008 Dec;60(12):1643-50
pubmed: 19000369
Arthritis Res Ther. 2007;9 Suppl 1:S2
pubmed: 17634141
Scand J Rheumatol. 2015 May;44(3):182-91
pubmed: 25439190
Mediators Inflamm. 2015;2015:564042
pubmed: 26347311
J Neurosci Methods. 2018 Apr 15;300:92-102
pubmed: 28445709
Neural Regen Res. 2012 Oct 15;7(29):2259-66
pubmed: 25538747
Inflammation. 2012 Apr;35(2):560-5
pubmed: 21603970
Arthritis Rheum. 2002 Aug;47(4):391-7
pubmed: 12209485